Adlai Nortye Group Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ANL | ADAG | ONCO.ST | RCUS | AKTS | SNDX | |
|---|---|---|---|---|---|---|
| Market cap | 618.86M | 161.82M | 741.07M | 2.43B | 845.42M | 940.80M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -32.7 | -4.3 | -2.4 | -6.2 | -7.1 | -14.4 |
| Price/book | 2.9 | 1.8 | 27.3 | 3.8 | 1.7 | -54.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +520.00% | +49.69% | −63.90% | −1.28% | −32.14% | −28.86% |
| Today | +0.31% | +2.55% | −0.35% | +2.12% | +1.74% | −26.87% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ANL news ›Adlai Nortye (NASDAQ:ANL) Cut to Hold at Wall Street Zen
Posted by Sarita Garza on Nov 3rd, 2026 Wall Street Zen cut shares of Adlai Nortye (NASDAQ:ANL – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports. Get Our…
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial Cetuximab will be supplied by Lilly for the U.S. trial sites…
Adlai Nortye Ltd. Sponsored ADR (ANL) – What Are Brokerages Saying About This Stock?
Posted by Sarita Garza on Oct 25th, 2026 Get Our Latest Research Report on ANL NASDAQ ANL opened at $10.58 on Friday. The firm’s fifty day moving average is $14.20 and its two-hundred day moving average is $12.82. Adlai Nortye has a one…
Adlai Nortye (NASDAQ:ANL) Stock Falls 4.1% – Should You Sell?
Posted by Sarita Garza on Oct 21st, 2026 Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report)’s share price traded down 4.1% during mid-day trading on Monday. The company traded as low as $10.58 and last traded at $10.5790.…
Adlai Nortye to Work With Eli Lilly, Merck on Trial for Cancer Treatment
Published on 10/15/2026 at 09:07 am EDT - Modified on 10/15/2026 at 09:10 am EDT Adlai Nortye Group inked agreements for Eli Lilly and Merck to work on a trial for its AN4035, which is in development to treat certain types of tumors. The…
Adlai Nortye Enters Clinical Trial Deals With Eli Lilly, Merck KGaA
Adlai Nortye signed clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA to evaluate its investigational cancer drug AN4035 in combination with cetuximab, the company... Adlai Nortye Group Ltd. Biotechnology &…
Adlai Nortye Group: Only For The Risk-Tolerant After A Massive Rally
Adlai Nortye Group has surged ~1,600% since Dec. 2025, fueled by private placements and preclinical data for its pan-RAS[ON] inhibitor AN9025. Learn more about ANL stock here. - Adlai Nortye Group has surged ~1,600% since Dec. 2025, fueled…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com3
- marketscreener.com2
- financial-news.co.uk1
- markets.businessinsider.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.